Home Sectors Healthcare Buy or Sell: Luminex Corporation (NASDAQ: LMNX)

Buy or Sell: Luminex Corporation (NASDAQ: LMNX)


Luminex Corporation trades as part of the healthcare sector and is in the medical instruments and equipment industry. The company CEO is Nachum Shamir. Luminex Corp develops, manufactures and sells proprietary biological testing technologies and products with applications throughout the life sciences and diagnostics industries. Its products include MAGPIX, Luminex 100/200, and FLEXMAP 3D.

Previous Intraday Trading Performance:

The LMNX stock showed a previous change of 0.09% with an open at 21.78 and a close of 21.73. It reached an intraday high of 21.79 and a low of 21.46.

PR Newswire:  EDP Biotech to Develop and Market Colorectal Cancer Early Detection Blood Test Using Luminex xMAP® Technology


The stock has a market cap of $977.4m with 45.0m shares outstanding, of which the float is 41.2m shares. Trading volume reached 223,615 shares compared to its average volume of 287,512 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Luminex Corporation shares returned 0.79% and in the past 30 trading days it returned -5.93%. Over three months, it changed -9.76%. In one year it has changed -26.70% and within that year its 52-week high was 35.37 and its 52-week low was 20.24. LMNX stock is 7.36% above its 52 Week Low.

Our calculations show a 200 day moving average of 25.37 and a 50 day moving average of 22.15. Currently LMNX stock is trading -14.33% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

PR Newswire:  EDP Biotech to Develop and Market Colorectal Cancer Early Detection Blood Test Using Luminex xMAP® Technology


The last annual fiscal EPS for the company was reported at 0.42 that ended on 31st of December 2018, which according to the previous close, that is a PE of 51.74. Based on 5 analyst estimates, the consensus EPS for the next quarter is 0.07. The TTM EPS is 0.49, which comes to a TTM PE of 44.35. Historically, the PE high was 127.60 and the PE low was 16.40. If the stock reached its PE low, that would represent a price of 8.04, which is a decrease of -63.02%.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/06/2019): 0.07
4thQtr of 2018 (Reported on 02/04/2019): -0.05
3rdQtr of 2018 (Reported on 11/05/2018): 0.04
2ndQtr of 2018 (Reported on 08/06/2018): 0.13
1stQtr of 2018 (Reported on 05/07/2018): 0.30

The dividend per share is currently 0.24, which is a dividend yield of 1.10%. Also, the payout ratio is 48.98%, therefore the dividend is safe according to our calculations.

Base on our calculations, the intrinsic value per share is 12.47, which means it may be overvalued by -74.27%.

Indicators to Watch:

The current calculated beta is 0.80.

SeekingAlpha:  Ruby Tuesday board rejects Boaz Group offer

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 1.79%, return on assets is 1.58%, profit margin is 2.67%, price-to-sales is 3.15 and price-to-book is 2.08.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 0  :Past Performance Score
 6  :Financial Strength Score
 4  :Future Growth Score
 1  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.